Assyro AI

Orange Book product · Brand (NDA)

CAMCEVI KIT

LEUPROLIDE MESYLATE

Brand (NDA)NDA 211488RX ACCORD

At a glance

May 25, 2021

Approved

Brand (NDA)

Application

Not listed

TE code

5

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    May 25, 2021

    5 yr 2 mo ago

  2. Today

  3. Patent 10646572 expires

    Listed drug product patent expiration.

    Jan 16, 2027

    in 7 mo

  4. Patent 9744207 expires

    Listed drug product patent expiration.

    Jan 16, 2027

    in 7 mo

  5. Patent 9572857 expires

    Listed drug product patent expiration.

    Aug 02, 2029

    in 3 yr 2 mo

  6. Patent 12133878 expires

    Listed drug product patent expiration.

    Dec 18, 2037

    in 11 yr 8 mo

  7. Patent 11717555 expires

    Listed drug product patent expiration.

    Jan 01, 2039

    in 12 yr 9 mo

Pharmaceutical detail

Active ingredient

LEUPROLIDE MESYLATE

Strength

EQ 42MG BASE

Dosage form

EMULSION

Route

SUBCUTANEOUS

TE code

Not listed

Application

NDA 211488

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (5)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10646572Jan 16, 2027in 7 mo
Product
9744207Jan 16, 2027in 7 mo
Product
9572857Aug 02, 2029in 3 yr 2 mo
Product
12133878Dec 18, 2037in 11 yr 8 mo
Product
11717555Jan 01, 2039in 12 yr 9 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.